Drug-induced toxicity on mitochondria and lipid metabolism: Mechanistic diversity and deleterious consequences for the liver

Journal of Hepatology

Volumn 54, Issue 4, 2011, Pages 773-794

  Begriche, Karima ^a   Massart, Julie ^b   Robin, Marie Anne ^b   Borgne Sanchez, Annie ^c   Fromenty, Bernard ^b  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b INSERM   (France)

^c HÔPITAL ROBERT DEBRÉ   (France)

Author keywords

Cell death; Drugs; Hepatotoxicity; Lipids; Mitochondria; Obesity; Oxidative stress; Steatosis

Indexed keywords

ADIPONECTIN; ALPIDEM; AMIODARONE; BUPRENORPHINE; CYTOCHROME C; DICLOFENAC; DIDANOSINE; DISULFIRAM; FIALURIDINE; IBUPROFEN; LEPTIN; NILUTAMIDE; NIMESULIDE; PANADIPLON; PARACETAMOL; PERHEXILINE; PIRPROFEN; PROTEIN BCL 2; REACTIVE OXYGEN METABOLITE; RNA DIRECTED DNA POLYMERASE INHIBITOR; SALICYLIC ACID; STAVUDINE; TACRINE; TAMOXIFEN; TETRACYCLINE; TROGLITAZONE; UNINDEXED DRUG; VALPROIC ACID; VERY LOW DENSITY LIPOPROTEIN; ZIDOVUDINE;

ALCOHOL INTOXICATION; CARBOHYDRATE METABOLISM; CELL DEATH; DISEASE COURSE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DNA DAMAGE; DNA REPAIR; FATTY ACID OXIDATION; FATTY LIVER; GENETIC PREDISPOSITION; HEPATITIS C; HOMEOSTASIS; HUMAN; INSULIN RESISTANCE; LIPID METABOLISM; LIPID STORAGE; LIPOGENESIS; LIVER CELL; LIVER METABOLISM; LIVER MITOCHONDRION; LIVER TOXICITY; MEMBRANE PERMEABILITY; MITOCHONDRIAL DNA DEPLETION; MITOCHONDRIAL GENOME; MITOCHONDRIAL MEMBRANE; MITOCHONDRIAL RESPIRATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; STEATOSIS;

ADIPONECTIN; ADIPOSE TISSUE; ALCOHOLIC INTOXICATION; ANIMALS; CARBOHYDRATE METABOLISM; CELL DEATH; DIABETES MELLITUS, TYPE 2; DRUG-INDUCED LIVER INJURY; ENERGY METABOLISM; FATTY ACIDS; FATTY LIVER; GENETIC PREDISPOSITION TO DISEASE; GENOME, MITOCHONDRIAL; HEPATITIS C; HUMANS; INSULIN RESISTANCE; LEPTIN; LIPID METABOLISM; MITOCHONDRIA, LIVER; MITOCHONDRIAL MEMBRANE TRANSPORT PROTEINS; MODELS, BIOLOGICAL; OBESITY; OXIDATION-REDUCTION; OXIDATIVE PHOSPHORYLATION; REACTIVE OXYGEN SPECIES;

EID: 79952702137     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2010.11.006     Document Type: Review

References (350)

1. Biour M, Ben Salem C, Chazouillères O, Grangé JD, Serfaty L, Poupon R. Drug-induced liver injury; fourteenth updated edition of the bibliographic database of liver injuries and related drugs. Gastroenterol Clin Biol 2004;28:720-759. (Pubitemid 39318162)
2. Larrey D. Drug-induced liver diseases. J Hepatol 2000;32:77-88. (Pubitemid 30123626)
3. Björnsson E. The natural history of drug-induced liver injury. Semin Liver Dis 2009;29:357-363.
4. Lammert C, Bjornsson E, Niklasson A, Chalasani N. Oral medications with significant hepatic metabolism at higher for hepatic adverse events. Hepatology 2009;51:615-620.
5. Fromenty B, Pessayre D. Inhibition of mitochondrial beta-oxidation as a mechanism of hepatotoxicity. Pharmacol Ther 1995;67:101-154.
6. Labbe G, Pessayre D, Fromenty B. Drug-induced liver injury through mitochondrial dysfunction: mechanisms and detection during preclinical safety studies. Fundam Clin Pharmacol 2008;22:335-353.
7. Pessayre D, Mansouri A, Berson A, Fromenty B. Mitochondrial involvement in drug-induced liver injury. Handb Exp Pharmacol 2010;196:311-365.
8. Masubuchi Y, Suda C, Horie T. Involvement of mitochondrial permeability transition in acetaminophen-induced liver injury in mice. J Hepatol 2005;42:110-116. (Pubitemid 40038908)
9. Mitchell P. The ninth sir hans Krebs lecture. Compartmentation and communication in living systems. Ligand conduction: a general catalytic principle in chemical, osmotic and chemiosmotic reaction systems. Eur J Biochem 1979;95:1-20. (Pubitemid 9229057)
10. Bernardi P, Krauskopf A, Basso E, Petronilli V, Blachly-Dyson E, Di Lisa F, et al. The mitochondrial permeability transition from in vitro artifact to disease target. FEBS J 2006;27:2077-2099.
11. Di Lisa F, Bernardi P. A CaPful of mechanisms regulating the mitochondrial permeability transition. J Mol Cell Cardiol 2009;46:775-780.
12. Malhi H, Gores GJ, Lemasters JJ. Apoptosis and necrosis in the liver: a tale of two deaths? Hepatology 2006;43:S31-S44.
13. Fulda S, Galluzzi L, Kroemer G. Targeting mitochondria for cancer therapy. Nat Rev Drug Discov 2010;9:447-464.
14. Pessayre D, Haouzi D, Fau D, Robin MA, Mansouri A, Berson A. Withdrawal of life support, altruistic suicide, fratricidal killing and euthanasia by lymphocytes: different forms of drug-induced hepatic apoptosis. J Hepatol 1999;31:760-770. (Pubitemid 29487702)
15. Kroemer G, Reed JC. Mitochondrial control of cell death. Nat Med 2000;6:513-519. (Pubitemid 30305900)
16. Buron N, Porceddu M, Brabant M, Desgué D, Racoeur C, Lassalle M, et al. PLoS One 2010;5:e9924.
17. Balakirev MY, Zimmer G. Mitochondrial injury by disulfiram: two different mechanisms of the mitochondrial permeability transition. Chem Biol Interact 2001;138:299-311. (Pubitemid 33063642)
18. 2+-induced pore: tissue specificity, age profile and dependence on the animal's adaptation to hypoxia. J Bioenerg Biomembr 2009;41:395-401.
19. Eliseev RA, Filippov G, Velos J, VanWinkle B, Goldman A, Rosier RN, et al. Role of cyclophilin D in the resistance of brain mitochondria to the permeability transition. Neurobiol Aging 2007;28:1532-1542. (Pubitemid 47238534)
20. Mirandola SR, Melo DR, Saito A, Castilho RF. 3-Nitropropionic acid-induced mitochondrial permeability transition: comparative study of mitochondria from different tissues and brain regions. J Neurosci Res 2010;88:630-639.
21. Maianski NA, Geissler J, Srinivasula SM, Alnemri ES, Roos D, Kuijpers TW. Functional characterization of mitochondria in neutrophils: a role restricted to apoptosis. Cell Death Differ 2004;11:143-153. (Pubitemid 38159638)
22. Wallace DC, Fan W, Procaccio V. Mitochondrial energetics and therapeutics. Annu Rev Pathol 2010;5:297-348.
23. Faye A, Borthwick K, Esnous C, Price NT, Gobin S, Jackson VN, et al. Demonstration of N- and C-terminal domain intramolecular interactions in rat liver carnitine palmitoyltransferase 1 that determine its degree of malonyl-CoA sensitivity. Biochem J 2005;387:67-76. (Pubitemid 40524075)
24. McGarry JD, Leatherman GF, Carnitine FosterDW. Carnitine palmitoyltransferase I. The site of inhibition of hepatic fatty acid oxidation by malonyl-CoA. J Biol Chem 1978;253:4128-4136. (Pubitemid 8380630)
25. Hashimoto T, Cook WS, Qi C, Yeldandi AV, Reddy JK, Rao MS. Defect in peroxisome proliferator-activated receptor alpha-inducible fatty acid oxidation determines the severity of hepatic steatosis in response to fasting. J Biol Chem 2000;275:28918-28928.
26. Shekhawat PS, Matern D, Strauss AW. Fetal fatty acid oxidation disorders, their effect on maternal health and neonatal outcome: impact of expanded newborn screening on their diagnosis and management. Pediatr Res 2005;57:78R-86R.
27. Derks TG, van Dijk TH, Grefhorst A, Rake JP, Smit GP, Kuipers F, et al. Inhibition of mitochondrial fatty acid oxidation in vivo only slightly suppresses gluconeogenesis but enhances clearance of glucose in mice. Hepatology 2008;47:1032-1042. (Pubitemid 351449694)
28. Senior AE, Sherratt HS. A comparison of the effects on blood glucose and ketone-body levels, and of the toxicities, of pent-4-enoic acid and four simple fatty acids. J Pharm Pharmacol 1969;21:85-92.
29. Wallace DC. A mitochondrial paradigm of metabolic and degenerative diseases, aging, and cancer: a dawn for evolutionary medicine. Annu Rev Genet 2005;39:359-407. (Pubitemid 43011120)
30. Fromenty B, Fisch C, Berson A, Lettéron P, Larrey D, Pessayre D. Dual effect of amiodarone on mitochondrial respiration. Initial protonophoric uncoupling effect followed by inhibition of the respiratory chain at the levels of complex I and II. J Pharmacol Exp Ther 1990;255:1377-1384.
31. Seifert EL, Estey C, Xuan JY, Harper ME. Electron transport chain-dependent and -independent mechanisms of mitochondrial H2O2 emission during long-chain fatty acid oxidation. J Biol Chem 2010;285:5748-5758.
32. Mari M, Morales A, Colell A, Garcia-Ruiz C, Fernandez-Checa JC. Mitochondrial glutathione, a key survival antioxidant. Antioxid Redox Signal 2009;11:2685-2700.
33. Fernandez-Checa JC, Kaplowitz N. Hepatic mitochondrial glutathione: transport and role in disease and toxicity. Toxicol Appl Pharmacol 2005;204:263-273. (Pubitemid 40545231)
34. Jones DP, Lemasters JJ, Han D, Boelsterli UA, Kaplowitz N. Mechanisms of pathogenesis in drug hepatotoxicity. Putting the stress on mitochondria. Mol Interv 2010;10:98-111.
35. Brookes PS. Mitochondrial H(+) leak and ROS generation: an odd couple. Free Radic Biol Med 2005;38:12-23.
36. Tahara EB, Navarete FD, Kowaltowski AJ. Tissue-, substrate- and site-specific characteristics of mitochondrial reactive oxygen species generation. Free Radic Biol Med 2009;46:1283-1297.
37. Demeilliers C, Maisonneuve C, Grodet A, Mansouri A, Nguyen R, Tinel M, et al. Impaired adaptive resynthesis and prolonged depletion of hepatic mitochondrial DNA after repeated alcohol binges in mice. Gastroenterology 2002;123:1278-1290.
38. Sanz A, Caro P, Ayala V, Portero-Otin M, Pamplona R, Barja G. Methionine restriction decreases mitochondrial oxygen radical generation and leak as well as oxidative damage to mitochondrial DNA and proteins. FASEB J 2006;20:1064-1073. (Pubitemid 44943902)
39. Velsor LW, Kovacevic M, Goldstein M, Leitner HM, Lewis W, Day BJ. Mitochondrial oxidative stress in human hepatoma cells exposed to stavudine. Toxicol Appl Pharmacol 2004;199:10-19. (Pubitemid 39099451)
40. Fromenty B, Robin MA, Igoudjil A, Mansouri A, Pessayre D. The ins and outs of mitochondrial dysfunction in NASH. Diabetes Metab 2004;30:121-138. (Pubitemid 38715168)
41. Igoudjil A, Begriche K, Pessayre D, Fromenty B. Mitochondrial, metabolic and genotoxic effects of antiretroviral nucleoside reverse-transcriptase inhibitors. Anti-Infective Agents in Medicinal Chemistry 2006;5:273-292. (Pubitemid 44027706)
42. Wallace DC, Fan W. Energetics, epigenetics, mitochondrial genetics. Mitochondrion 2010;10:12-31.
43. Kim I, Rodriguez-Enriquez S, Lemasters JJ. Selective degradation of mitochondria by autophagia. Arch Biochem Biophys 2007;462:245-253.
44. Ducluzeau PH, Lachaux A, Bouvier R, Duborjal H, Stepien G, Bozon D, et al. Progressive reversion of clinical and molecular phenotype in a child with liver mitochondrial DNA depletion. J Hepatol 2002;36:698-703. (Pubitemid 34499410)
45. Rossignol R, Faustin B, Rocher C, Malgat M, Mazat JP, Letellier T. Mitochondrial threshold effects. Biochem J 2003;370:751-762. (Pubitemid 36399067)
46. Croteau DL, Stierum RH, Bohr VA. Mitochondrial DNA repair pathways. Mutat Res 1999;434:137-148. (Pubitemid 29352252)
47. Dianov GL, Souza-Pinto N, Nyaga SG, Thybo T, Stevnsner T, Bohr VA. Base excision repair in nuclear and mitochondrial DNA. Prog Nucleic Acid Res Mol Biol 2001;68:285-297. (Pubitemid 33804669)
48. Schönfeld P, Dymkowska D, Wojtczal L. Acyl-CoA-induced generation of reactive oxygen species in mitochondrial preparations is due to the presence of peroxisomes. Free Radic Biol Med 2009;47:503-509.
49. 2 production in the unanaesthetized mouse. Biochem J 1984;218:697-702.
50. Arnaiz SL, Travacio M, Llesuy S, Boveris A. Hydrogen peroxide metabolism during peroxisome proliferation by fenofibrate. Biochim Biophys Acta 1995;1272:175-180. (Pubitemid 26009138)
51. Hardwick JP. Cytochrome P450 omega hydroxylase (CYP4) function in fatty acid metabolism and metabolic diseases. Biochem Pharmacol 2008;75:2263-2275.
52. Laethem RM, Balazy M, Falck JR, Laethem CL, Koop DR. Formation of 19(S)-, 19(R)-, and 18(R)-hydroxyeicosatetraenoic acids by alcohol-inducible cytochrome P450 2E1. J Biol Chem 1993;268:12912-12918.
53. Passi S, Picardo M, Nazzaro-Porro M, Breathnach A, Confaloni AM, Serlupi-Crescenzi G. Antimitochondrial effect of saturated medium chain length (C8-C13) dicarboxylic acids. Biochem Pharmacol 1984;33:103-108.
54. Bai J, Cederbaum AI. Overexpression of CYP2E1 in mitochondria sensitizes HepG2 cells to the toxicity caused by depletion of glutathione. J Biol Chem 2006;281:5128-5136. (Pubitemid 43847778)
55. Bansal S, Liu CP, Sepuri NB, Anandatheerthavarada HK, Selvaraj V, Hoek J, et al. Mitochondria-targeted cytochrome P450 2E1 induces oxidative damage and augments alcohol-mediated oxidative stress. J Biol Chem 2010;285:24609-24619.
56. Robin MA, Anandatheerthavarada HK, Biswas G, Sepuri NB, Gordon DM, Pain D, et al. Bimodal targeting of microsomal CYP2E1 to mitochondria through activation of an N-terminal chimeric signal by cAMP-mediated phosphorylation. J Biol Chem 2002;277:40583-40593. (Pubitemid 35215638)
57. Alaynick WA. Nuclear receptors, mitochondria and lipid metabolism. Mitochondrion 2008;8:329-337.
58. Hsu MH, Savas U, Griffin KJ, Johnson EF. Identification of peroxisome proliferator-responsive human genes by elevated expression of the peroxisome proliferator-activated receptor alpha in HepG2 cells. J Biol Chem 2001;276:27950-27958.
59. Schoonjans K, Staels B, Auwerx J. The peroxisome proliferator activated receptors (PPARs) and their effects on lipid metabolism and adipocyte differentiation. Biochim Biophys Acta 1996;1302:93-109. (Pubitemid 26247079)
60. Begriche K, Knockaert L, Massart J, Robin MA, Fromenty B. Mitochondrial dysfunction in nonalcoholic steatohepatitis (NASH): are there drugs able to improve it? Drug Discov Today Dis Mech 2009;6:e11-e23.
61. Desvergne B, Feige JN, Casals-Casas C. PPAR-mediated activity of phthalates: a link to the obesity epidemic? Mol Cell Endocrinol 2009;304:43-48.
62. Moreau A, Téruel C, Beylot M, Albalea V, Tamasi V, Umbdenstock T, et al. A novel pregnane X receptor and S14-mediated lipogenic pathway in human hepatocytes. Hepatology 2009;49:2068-2079.
63. Kamagate A, Qu S, Perdomo G, Su D, Kim DH, Slusher S, et al. FoxO1 mediates insulin-dependent regulation of hepatic VLDL production in mice. J Clin Invest 2008;118:2347-2364. (Pubitemid 351872351)
64. Pardina E, Baena-Fustegueras JA, Llamas R, Catalan R, Galard R, Lecube A, et al. Lipoprotein lipase expression in livers of morbidly obese patients could be responsible for liver steatosis. Obes Surg 2009;19:608-616.
65. Ahima RS. Adipose tissue as an endocrine organ. Obesity 2006;14:242S-249S.
66. Begriche K, Massart J, Fromenty B. Effects of b-aminoisobutyric acid on leptin production and lipid homeostasis: mechanisms and possible relevance for the prevention of obesity. Fundam Clin Pharmacol 2010;24:269-282.
67. Yamauchi T, Kamon J, Minokoshi Y, Ito Y, Waki H, Uchida S, et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 2002;8:1288-1295. (Pubitemid 35373562)
68. Kalra SP. Central leptin gene therapy ameliorates diabetes type 1 and 2 through two independent hypothalamic relays; a benefit beyond weight and appetite regulation. Peptides 2009;30:1957-1963.
69. Begriche K, Lettéron P, Abbey-Toby A, Vadrot N, Robin MA, Bado A, et al. Partial leptin deficiency favors diet-induced obesity and related metabolic disorders in mice. Am J Physiol Endocrinol Metab 2008;294:E939-E951.
70. Farooqi IS, O'Rahilly S. Leptin: a pivotal regulator of human energy homeostasis. Am J Clin Nutr 2009;89:980S-984S.
71. Marra F, Bertolani C. Adipokines in liver diseases. Hepatology 2009;50:957-969.
72. Zhou M, Xu A, Tam PK, Lam KS, Chan L, Hoo RL, et al. Mitochondrial dysfunction contributes to the increased vulnerabilities of adiponectin knockout mice to liver injury. Hepatology 2008;48:1087-1096.
73. Gerber N, Dickinson RG, Harland RC, Lynn RK, Houghton LD, Antonias JI, et al. Reye-like syndrome associated with valproic acid therapy. J Pediatr 1979;95:142-144. (Pubitemid 9183702)
74. Zimmerman HJ, Ishak KG. Valproate-induced hepatic injury: analyses of 23 fatal cases. Hepatology 1982;2:591-597. (Pubitemid 13173942)
75. Arnaudo E, Dalakas M, Shanske S, Moraes CT, DiMauro S, Schon EA. Depletion of muscle mitochondrial DNA in AIDS patients with zidovudine-induced myopathy. Lancet 1991;337:508-510.
76. Lai KK, Gang DL, Zawacki JK, Cooley TP. Fulminant hepatic failure associated with 20,30-dideoxyinosine (ddI). Ann Intern Med 1991;115:283-284.
77. Le Bras P, D'Oiron R, Quertainmont Y, Halfon P, Caquet R. Metabolic, hepatic and muscular changes during zidovudine therapy: a drug-induced mitochondrial disease? AIDS 1994;8:716-717.
78. Nadanaciva S, Will Y. The role of mitochondrial dysfunction and drug safety. IDrugs 2009;12:706-710.
79. Jaeschke H, Gores GJ, Cederbaum AI, Hinson JA, Pessayre D, Lemasters JJ. Mechanisms of hepatotoxicity. Toxicol Sci 2002;65:166-176. (Pubitemid 34121108)
80. Ramaiah SK, Jaeschke H. Role of neutrophils in the pathogenesis of acute inflammatory liver injury. Toxicol Pathol 2007;35:757-766. (Pubitemid 47613608)
81. Lawson JA, Fisher MA, Simmons CA, Farhood A, Jaeschke H. Inhibition of Fas receptor (CD95)-induced hepatic caspase activation and apoptosis by acetaminophen in mice. Toxicol Appl Pharmacol 1999;156:179-186. (Pubitemid 29222632)
82. Bajt ML, Ho YS, Vonderfecht SL, Jaeschke H. Reactive oxygen as modulator of TNF and fas receptor-mediated apoptosis in vivo: studies with glutathione peroxidase-deficient mice. Antioxid Redox Signal 2002;4:733-740. (Pubitemid 35246935)
83. Berson A, Cazanave S, Descatoire V, Tinel M, Grodet A, Wolf C, et al. The anti-inflammatory drug, nimesulide (4-nitro-2-phenoxymethane-sulfoanilide), uncouples mitochondria and induces mitochondrial permeability transition in human hepatoma cells: protection by albumin. J Pharmacol Exp Ther 2006;318:444-454.
84. Kaufmann P, Török M, Hänni A, Roberts P, Gasser R, Krähenbühl S. Mechanisms of benzarone and benzbromarone-induced hepatic toxicity. Hepatology 2005;41:925-935. (Pubitemid 40462955)
85. Trost LC, Lemasters JJ. The mitochondrial permeability transition: a new pathophysiological mechanism for Reye's syndrome and toxic liver injury. J Pharmacol Exp Ther 1996;278:1000-1005. (Pubitemid 27166945)
86. Berson A, Descatoire V, Sutton A, Fau D, Maulny B, Vadrot N, et al. Toxicity of alpidem, a peripheral benzodiazepine receptor ligand, but not zolpidem, in rat hepatocytes: role of mitochondrial permeability transition and metabolic activation. J Pharmacol Exp Ther 2001;299:793-800.
87. Masubuchi Y, Kano S, Horie T. Mitochondrial permeability transition as a potential determinant of hepatotoxicity of antidiabetic thiazolidinediones. Toxicology 2006;222:233-239.
88. Kowaltowski AJ, Castilho RF, Vercesi AE. Mitochondrial permeability transition and oxidative stress. FEBS Lett 2001;495:12-15. (Pubitemid 32367965)
89. Hinson JA, Roberts DW, James LP. Mechanisms of acetaminophen-induced liver necrosis. Handb Exp Pharmacol 2010;196:369-405.
90. Burcham PC, Harman AW. Acetaminophen toxicity results in site-specific mitochondrial damage in isolated mouse hepatocytes. J Biol Chem 1991;266:5049-5054. (Pubitemid 21909459)
91. Chen C, Krausz KW, Shah YM, Idle JR, Gonzalez FJ. Serum metabolomics reveals irreversible inhibition of fatty acid β-oxidation through the suppression of PPARa activation as a contributing mechanism of acetaminophen-induced hepatotoxicity. Chem Res Toxicol 2009;22:699-707.
92. Ruepp SU, Tonge RP, Shaw J, Wallis N, Pognan F. Genomics and proteomics analysis of acetaminophen toxicity in mouse liver. Toxicol Sci 2002;65:135-150. (Pubitemid 34092698)
93. Kaplowitz N, Shinohara M, Liu ZX, Han D. How to protect against acetaminophen: don't ask for JUNK. Gastroenterology 2008;135:1047-1051.
94. Sohn JH, Han KL, Kim JH, Rukayadi Y, Hwang JK. Protective effects of macelignan on cisplatin-induced hepatotoxicity is associated with JNK activation. Biol Pharm Bull 2008;31:273-277. (Pubitemid 351198405)
95. Dong Z, Saikumar P, Weinberg JM, Venkatachalam MA. Internucleosomal DNA cleavage triggered by plasma membrane damage during necrotic cell death. Involvement of serine but not cysteine proteases. Am J Pathol 1997;151:1205-1213. (Pubitemid 27479749)
96. Berson A, Renault S, Lettéron P, Robin MA, Fromenty B, Fau D, et al. Uncoupling of rat and human mitochondria: a possible explanation for tacrine-induced liver dysfunction. Gastroenterology 1996;110:1878-1890. (Pubitemid 26169225)
97. Tokumitsu Y, Lee S, Ui M. In vitro effects of nonsteroidal anti-inflammatory drugs on oxidative phosphorylation in rats liver mitochondria. Biochem Pharmacol 1977;26:2101-2106.
98. Lim MS, Lim PL, Gupta R, Boelsterli UA. Critical role of free cytosolic calcium, but not uncoupling, in mitochondrial permeability transition and cell death induced by diclofenac oxidative metabolites in immortalized human hepatocytes. Toxicol Appl Pharmacol 2006;217:322-331. (Pubitemid 44855823)
99. Berson A, Fau D, Fornacciari R, Degove-Goddard P, Sutton A, Descatoire V, et al. Mechanisms for experimental buprenorphine hepatotoxicity: major role of mitochondrial dysfunction versus metabolic activation. J Hepatol 2001;34:261-269. (Pubitemid 32176448)
100. Card JW, Lalonde BR, Rafeiro E, Tam AS, Racz WJ, Brien JF, et al. Amiodarone-induced disruption of hamster lung and liver mitochondrial function: lack of association with thiobarbituric acid-reactive substance production. Toxicol Lett 1998;98:41-50. (Pubitemid 28403567)
101. Deschamps D, DeBeco V, Fisch C, Fromenty B, Guillouzo A, Pessayre D. Inhibition by perhexiline of oxidative phosphorylation and the β-oxidation of fatty acids: possible role in pseudoalcoholic liver lesions. Hepatology 1994;19:948-961.
102. Larosche I, Lettéron P, Fromenty B, Vadrot N, Abbey-Toby A, Feldmann G, et al. Tamoxifen inhibits topoisomerases, depletes mitochondrial DNA, and triggers steatosis in mouse liver. J Pharmacol Exp Ther 2007;321:526-535. (Pubitemid 46624526)
103. Waldhauser KM, Török M, Ha HR, Thomet U, Konrad D, Brecht K, et al. Hepatocellular toxicity and pharmacological effect of amiodarone and amiodarone derivatives. J Pharmacol Exp Ther 2006;319:1413-1423.
104. Deschamps D, Fisch C, Fromenty B, Berson A, Degott C, Pessayre D. Inhibition by salicylic acid of the activation and thus oxidation of long chain fatty acids. Possible role in the development of Reye's syndrome. J Pharmacol Exp Ther 1991;259:894-904.
105. Doi H, Horie T. Salicylic acid-induced hepatotoxicity triggered by oxidative stress. Chem Biol Interact 2010;183:363-368.
106. Fromenty B, Fisch C, Labbe G, Degott C, Deschamps D, Berson A, et al. Amiodarone inhibits the mitochondrial b-oxidation of fatty acids and produces microvesicular steatosis of the liver in mice. J Pharmacol Exp Ther 1990;255:1371-1376.
107. Kennedy JA, Unger SA, Horowitz JD. Inhibition of carnitine palmitoyltransferase- 1 in rat heart and liver by perhexiline and amiodarone. Biochem Pharmacol 1996;52:273-280. (Pubitemid 26233756)
108. Berson A, Schmets L, Fisch C, Fau D, Wolf C, Fromenty B, et al. Inhibition by nilutamide of the mitochondrial respiratory chain and ATP formation. Possible contribution to the adverse effects of this antiandrogen. J Pharmacol Exp Ther 1994;270:167-176. (Pubitemid 24229625)
109. Hautekeete ML, Degott C, Benhamou JP. Microvesicular steatosis of the liver. Acta Clin Belg 1990;45:311-326.
110. Coghlan ME, Sommadossi JP, Jhala NC, Many WJ, Saag MS, Johnson VA. Symptomatic lactic acidosis in hospitalized antiretroviral-treated patients with human immunodeficiency virus infection: a report of 12 cases. Clin Infect Dis 2001;33:1914-1921. (Pubitemid 33105134)
111. Danan G, Trunet P, Bernuau J, Degott C, Babany G, Pessayre D, et al. Pirprofen-induced fulminant hepatitis. Gastroenterology 1985;89:210-213. (Pubitemid 15057934)
112. Kleiner DE, Gaffey MJ, Sallie R, Tsokos M, Nichols L, McKenzie R, et al. Histopathologic changes associated with fialuridine hepatotoxicity. Mod Pathol 1997;10:192-199. (Pubitemid 27130467)
113. Le Bricquir Y, Larrey D, Blanc P, Pageaux GP, Michel H. Tianeptine: an instance of drug-induced hepatotoxicity predicted by prospective experimental studies. J Hepatol 1994;21:771-773. (Pubitemid 24374142)
114. Genève J, Hayat-Bonan B, Labbe G, Degott C, Lettéron P, Fréneaux E, et al. Inhibition of mitochondrial beta-oxidation of fatty acids by pirprofen. Role in microvesicular steatosis due to this nonsteroidal anti-inflammatory drug. J Pharmacol Exp Ther 1987;242:1133-1137. (Pubitemid 17156563)
115. Jones DB, Mullick FG, Hoofnagle JH, Baranski B. Reye's syndrome-like illness in a patient receiving amiodarone. Am J Gastroenterol 1988;83:967-969.
116. Lewis JH, Mullick F, Ishak KG, Ranard RC, Ragsdale B, Perse RM, et al. Histopathologic analysis of suspected amiodarone hepatotoxicity. Hum Pathol 1990;21:59-67.
117. Caldwell SH, Hespenheide EE, von Borstel RW. Myositis, microvesicular hepatitis, and progression to cirrhosis from troglitazone added to simvastatin. Dig Dis Sci 2001;46:376-378. (Pubitemid 32242688)
118. Fukano M, Amano S, Sato J, Yamamoto K, Adachi H, Okabe H, et al. Subacute hepatic failure associated with a new antidiabetic agent, troglitazone: a case report with autopsy examination. Hum Pathol 2000;31:250-253. (Pubitemid 30090658)
119. Kohlroser J, Mathai J, Reichheld J, Banner BF, Bonkovsky HL. Hepatotoxicity due to troglitazone: report of two cases and review of adverse events reported to the United States Food and Drug Administration. Am J Gastroenterol 2000;95:272-276. (Pubitemid 30041572)
120. Fromenty B, Grimbert S, Mansouri A, Beaugrand M, Erlinger S, Rötig A, et al. Hepatic mitochondrial DNA deletion in alcoholics: association with microvesicular steatosis. Gastroenterology 1995;108:193-200.
121. Rinaldo P, Yoon HR, Yu C, Raymond K, Tiozzo C, Giordano G. Sudden and unexpected neonatal death: a protocol for the postmortem diagnosis of fatty acid oxidation disorders. Semin Perinatol 1999;23:204-210. (Pubitemid 29211014)
122. Fréneaux E, Labbe G, Lettéron P, Le Dinh T, Degott C, Genève J, et al. Inhibition of the mitochondrial oxidation of fatty acids by tetracycline in mice and in man: possible role in microvesicular steatosis induced by this antibiotic. Hepatology 1988;8:1056-1062.
123. Renaud DL, Edwards V, Wilson GJ, Tein I. Glucose-free medium exacerbates microvesicular steatosis in cultured skin fibroblasts of genetic defects of fatty acid oxidation. A novel screening test. J Inherit Metab Dis 2002;25:547-555. (Pubitemid 36277624)
124. Lettéron P, Sutton A, Mansouri A, Fromenty B, Pessayre D. Inhibition of microsomal triglyceride transfer protein: another mechanism for drug-induced steatosis in mice. Hepatology 2003;38:133-140. (Pubitemid 36775804)
125. Wu X, Zhang L, Gurley E, Studer E, Shang J, Wang T, et al. Prevention of free fatty acid-induced hepatic lipotoxicity by 18-β-glycyrrhetinic acid through lysosomal and mitochondrial pathways. Hepatology 2008;47:1905-1915. (Pubitemid 351945558)
126. Matsumoto J, Ogawa H, Maeyama R, Okudaira K, Shinka T, Kuhara T, et al. Successful treatment by direct hemoperfusion of coma possibly resulting from mitochondrial dysfunction in acute valproate intoxication. Epilepsia 1997;38:950-953. (Pubitemid 27323607)
127. Baldwin GS, Murphy VJ, Yang Z, Hashimoto T. Binding of nonsteroidal antiinflammatory drugs to the α-subunit of the trifunctional protein of long chain fatty acid oxidation. J Pharmacol Exp Ther 1998;286:1110-1114. (Pubitemid 29003510)
128. Fromenty B, Fréneaux E, Labbe G, Deschamps D, Larrey D, Lettéron P, et al. Tianeptine, a new tricyclic antidepressant metabolized by beta-oxidation of its heptanoic side chain, inhibits the mitochondrial oxidation of medium and short chain fatty acids in mice. Biochem Pharmacol 1989;38:3743-3751. (Pubitemid 19284022)
129. Rettenmeier AW, Prickett KS, Gordon WP, Bjorge SM, Chang SL, Levy RH, et al. Studies on the biotransformation in the perfused rat liver of 2-n-propyl-4-pentenoic acid, a metabolite of the antiepileptic drug valproic acid. Evidence for the formation of chemically reactive intermediates. Drug Metab Dispos 1985;13:81-96. (Pubitemid 15169820)
130. Silva MF, Ruiter JP, Ijlst L, Jakobs C, Duran M, de Almeida IT, et al. Differential effect of valproate and its Delta2- and Delta4-unsaturated metabolites, on the beta-oxidation rate of long-chain and medium-chain fatty acids. Chem Biol Interact 2001;137:203-212. (Pubitemid 32879336)
131. Ramachandran R, Kakar S. Histological patterns in drug-induced liver disease. J Clin Pathol 2009;62:481-492.
132. Aires CC, Ijlst L, Stet F, Prip-Buus C, de Almeida IT, Duran M, et al. Inhibition of hepatic carnitine palmitoyl-transferase I (CPT IA) by valproyl-CoA as a possible mechanism of valproate-induced steatosis. Biochem Pharmacol 2010;79:792-799.
133. Fulgencio JP, Kohl C, Girard J, Pégorier JP. Troglitazone inhibits fatty acid oxidation and esterification, and gluconeogenesis in isolated hepatocytes from starved rats. Diabetes 1996;45:1556-1562. (Pubitemid 26357549)
134. Fréneaux E, Fromenty B, Berson A, Labbe G, Degott C, Lettéron P, et al. Stereoselective and nonstereoselective effects of ibuprofen enantiomers on mitochondrial beta-oxidation of fatty acids. J Pharmacol Exp Ther 1990;255:529-535.
135. Silva MF, Ruiter JP, Ijlst L, Allers P, ten Brink HJ, Jakobs C, et al. Synthesis and intramitochondrial levels of valproyl-coenzyme A metabolites. Anal Biochem 2001;290:60-67.
136. Yu HY, Wang BL, Zhao J, Yao XM, Gu Y, Li Y. Protective effect of bicyclol on tetracycline-induced fatty liver in mice. Toxicology 2009;261:112-118.
137. Lewis W, Levine ES, Griniuviene B, Tankersley KO, Colacino JM, Sommadossi JP, et al. Fialuridine and its metabolites inhibit DNA polymerase γ at sites of multiple adjacent analog incorporation, decrease mtDNA abundance, and cause mitochondrial structural defects in cultured hepatoblasts. Proc Natl Acad Sci USA 1996;93:3592-3597.
138. Walker UA, Venhoff N. Uridine in the prevention and treatment of NRTI-related mitochondrial toxicity. Antivir Ther 2005;10:M117-M123. (Pubitemid 41224948)
139. Cornejo-Juarez P, Sierra-Madero J, Volkow-Fernandez P. Metabolic acidosis and hepatic steatosis in two HIV-infected patients on stavudine (d4T) treatment. Arch Med Res 2003;34:64-69. (Pubitemid 36216344)
140. Walker UA, Bäuerle J, Laguno M, Murillas J, Mauss S, Schmutz G, et al. Depletion of mitochondrial DNA in liver under antiretroviral therapy with didanosine, stavudine, or zalcitabine. Hepatology 2004;39:311-317. (Pubitemid 38222171)
141. Cover C, Mansouri A, Knight TR, Bajt ML, Lemasters JJ, Pessayre D, et al. Peroxynitrite-induced mitochondrial and endonuclease-mediated nuclear DNA damage in acetaminophen hepatotoxicity. J Pharmacol Exp Ther 2005;315:879-887. (Pubitemid 41500754)
142. Rachek LI, Yuzefovych LV, Ledoux SP, Julie NL, Wilson GL. Troglitazone, but not rosiglitazone, damages mitochondrial DNA and induces mitochondrial dysfunction and cell death in human hepatocytes. Toxicol Appl Pharmacol 2009;240:348-354.
143. Ikeda S, Ozaki K. Action of mitochondrial endonuclease G on DNA damaged by L-ascorbic acid, peplomycin, and cis-diamminedichloroplatinum (II). Biochem Biophys Res Commun 1997;235:291-294. (Pubitemid 27313698)
144. Mansouri A, Gaou I, De Kerguenec C, Amsellem S, Haouzi D, Berson A, et al. An alcoholic binge causes massive degradation of hepatic mitochondrial DNA in mice. Gastroenterology 1999;117:181-190. (Pubitemid 29297636)
145. Rothfuss O, Gasser T, Patenge N. Analysis of differential DNA damage in the mitochondrial genome employing a semi-long run real-time PCR approach. Nucleic Acids Res 2010;38:e24.
146. de la Asuncion JG, del Olmo ML, Sastre J, Pallardo FV, Vina J. Zidovudine (AZT) causes an oxidation of mitochondrial DNA in mouse liver. Hepatology 1999;29:985-987. (Pubitemid 29109619)
147. Wu Y, Li N, Zhang T, Wu H, Huang C, Mitochondrial ChenD, et al. Base excision repair and mitochondrial DNA mutation in human hepatic HuH-7 cells exposed to stavudine. Mutat Res 2009;664:28-38.
148. Castéra L, Kalinsky E, Bedossa P, Tertian G, Buffet C. Macrovesicular steatosis induced by interferon alfa therapy for chronic myelogenous leukaemia. Liver 1999;19:259-260. (Pubitemid 29261594)
149. Farrell GC. Drugs and steatohepatitis. Semin Liver Dis 2002;22:185-194. (Pubitemid 34496471)
150. Grismer LE, Gill SA, Harris MD. Liver biopsy in psoriatic arthritis to detect methotrexate hepatotoxicity. J Clin Rheumatol 2001;7:224-227. (Pubitemid 32772081)
151. Zorzi D, Laurent A, Pawlik TM, Lauwers GY, Vauthey JN, Abdalla EK. Chemotherapy-associated hepatotoxicity and surgery for colorectal liver metastases. Br J Surg 2007;94:274-286. (Pubitemid 46423843)
152. Delzenne NM, Hernaux NA, Taper HS. A new model of acute liver steatosis induced in rats by fasting followed by refeeding a high carbohydrate-fat free diet. Biochemical and morphological analysis. J Hepatol 1997;26:880-885. (Pubitemid 27145713)
153. Bickel PE, Tansey JT, Welte MA. PAT proteins, an ancient family of lipid droplet proteins that regulate cellular lipid stores. Biochem Biophys Acta 2009;1791:419-440.
154. Brunt EM. Pathology of nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol 2010;7:195-203.
155. Begriche K, Igoudjil A, Pessayre D, Fromenty B. Mitochondrial dysfunction in NASH: causes, consequences and possible means to prevent it. Mitochondrion 2006;6:1-38. (Pubitemid 43250588)
156. Fabbrini E, Sullivan S, Klein S. Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications. Hepatology 2010;51:679-689.
157. Breitkopf K, Nagy LE, Beier JI, Mueller S, Weng H, Dooley S. Current experimental perspectives on the clinical progression of alcoholic liver disease. Alcohol Clin Exp Res 2009;33:1647-1655.
158. Crabb DW, Galli A, Fischer M, You M. Molecular mechanisms of alcoholic fatty liver: role of peroxisome proliferator-activated receptor alpha. Alcohol 2004;34:35-38.
159. Day CP, Yeaman SJ. The biochemistry of alcohol-induced fatty liver. Biochim Biophys Acta 1994;1215:33-48. (Pubitemid 24345053)
160. Donohue TM. Alcohol-induced steatosis in liver cells. World J Gastroenterol 2007;13:4974-4978.
161. Ji C, Chan C, Kaplowitz N. Predominant role of sterol response element binding proteins (SREBP) lipogenic pathways in hepatic steatosis in the murine intragastric ethanol feeding model. J Hepatol 2006;45:717-724. (Pubitemid 44479875)
162. Chen X, Sebastian BM, Tang H, McMullen MM, Axhemi A, Jacobsen DW, et al. Taurine supplementation prevents ethanol-induced decrease in serum adiponectin and reduces hepatic steatosis in rats. Hepatology 2009;49:1554-1562.
163. Song Z, Zhou Z, Deaciuc I, Chen T, McClain CJ. Inhibition of adiponectin production by homocysteine: a potential mechanism for alcoholic liver disease. Hepatology 2008;47:867-879. (Pubitemid 351449678)
164. Zeng T, Xie KQ. Ethanol and liver: recent advances in the mechanisms of ethanol-induced hepatosteatosis. Arch Toxicol 2009;83:1075-1081.
165. Jia Y, Viswakarma N, Fu T, Yu S, Rao MS, Borensztajn J, et al. Conditional ablation of mediator subunit MED1 (MED1/PPARBP) gene in mouse liver attenuates glucocorticoid receptor agonist dexamethasone-induced hepatic steatosis. Gene Expr 2009;14:291-306.
166. Lettéron P, Brahimi-Bourouina N, Robin MA, Moreau A, Feldmann G, Pessayre D. Glucocorticoids inhibit mitochondrial matrix acyl-CoA dehydrogenases and fatty acid beta-oxidation. Am J Physiol 1997;272:G1141-G1150.
167. Igoudjil A, Massart J, Begriche K, Descatoire V, Robin MA, Fromenty B. High concentrations of stavudine impair fatty acid oxidation without depleting mitochondrial DNA in cultured rat hepatocytes. Toxicol In Vitro 2008;22:887-898.
168. Chandler CE, Wilder DE, Pettini JL, Savoy YE, Petras SF, Chang G, et al. CP-346086: an MTP inhibitor that lowers plasma cholesterol and triglycerides in experimental animals and in humans. J Lipid Res 2003;44:1887-1901. (Pubitemid 37356661)
169. Wierzbicki AS, Hardman T, Prince WT. Future challenges for microsomal transport protein inhibitors. Curr Vasc Pharmacol 2009;7:277-286.
170. Blas-García A, Apostolova N, Ballesteros D, Monleón D, Morales JM, Rocha M, et al. Inhibition of mitochondrial function by efavirenz increases lipid content in hepatic cells. Hepatology 2010;52:115-125.
171. Thomson DM, Winder WW. AMP-activated protein kinase control of fat metabolism in skeletal muscle. Acta Physiol 2009;196:147-154.
172. Grunfeld C, Dinarello CA, Feingold KR. Tumor necrosis factor-α, interleukin-1, and interferon-α stimulate triglyceride synthesis in HepG2 cells. Metabolism 1991;40:894-898.
173. Gudbrandsen OA, Rost TH, Berge RK. Causes and prevention of tamoxifen-induced accumulation of triacylglycerol in rat liver. J Lipid Res 2006;47:2223-2232. (Pubitemid 44936133)
174. Macfarlane DP, Forbes S, Walker BR. Glucocorticoids and fatty acid metabolism in humans: fuelling fat redistribution in the metabolic syndrome. J Endocrinol 2008;197:189-204. (Pubitemid 351696232)
175. Schadinger SE, Bucher NL, Schreiber BM, Farmer SR. PPARγ2 regulates lipogenesis and lipid accumulation in steatotic hepatocytes. Am J Physiol Endocrinol Metab 2005;288:E1195-E1205. (Pubitemid 40726807)
176. Moya M, Gomez-Lechon MJ, Castell JV, Jover R. Enhanced steatosis by nuclear receptor ligands: a study in cultured human hepatocytes and hepatoma cells with a characterized nuclear receptor expression profile. Chem Biol Interact 2010;184:376-387.
177. Ekins S, Erickson JA. A pharmacophore for human pregnane X receptor ligands. Drug Metab Dispos 2002;30:96-99. (Pubitemid 34016946)
178. Harmsen S, Meijerman I, Beijnen JH, Schellens JH. Nuclear receptor mediated induction of cytochrome P450 3A4 by anticancer drugs: a key role for pregnane X receptor. Cancer Chemother Pharmacol 2009;64:35-43.
179. Bedoucha M, Atzpodien E, Boelsterli UA. Diabetic KKAy mice exhibit increased hepatic PPARγ1 gene expression and develop hepatic steatosis upon chronic treatment with antidiabetic thiazolidinediones. J Hepatol 2001;35:17-23. (Pubitemid 32646220)
180. Garcia-Ruiz I, Rodriguez-Juan C, Diaz-Sanjuan T, Martinez MA, Munoz-Yagüe T, Solis-Herruzo JA. Effects of rosiglitazone on the liver histology and mitochondrial function in ob/ob mice. Hepatology 2007;46:414-423. (Pubitemid 47344776)
181. Lemke U, Krones-Herzig A, Berriel Diaz M, Narvekar P, Ziegler A, Vegiopoulos A, et al. The glucocorticoid receptor controls hepatic dyslipidemia through Hes1. Cell Metab 2008;8:212-223.
182. Peffer RC, Moggs JG, Pastoor T, Currie RA, Wright J, Milburn G, et al. Mouse liver effects of cyproconazole, a triazole fungicide: role of the constitutive androstane receptor. Toxicol Sci 2007;99:315-325. (Pubitemid 47250388)
183. Baskin-Bey ES, Anan A, Isomoto H, Bronk SF, Gores GJ. Constitutive androstane receptor agonist, TCPOBOP, attenuates steatohepatitis in the methionine choline-deficient diet-fed mouse. World J Gastroenterol 2007;13:5635-5641. (Pubitemid 350031484)
184. Dong B, Saha PK, Huang W, Chen W, Abu-Elheiga LA, Wakil SJ, et al. Activation of nuclear receptor CAR ameliorates diabetes and fatty liver disease. Proc Natl Acad Sci USA 2009;106:18831-18836.
185. Gao J, He J, Zhai Y, Wada T, Xie W. The constitutive androstane receptor is an anti-obesity nuclear receptor that improves insulin sensitivity. J Biol Chem 2009;284:25984-25992.
186. Hu B, French SW. 2′,3′-Dideoxyinosine-induced Mallory bodies in patients with HIV. Am J Clin Pathol 1997;108:280-283. (Pubitemid 27371645)
187. Ozon A, Cetinkaya S, Alikasifoglu A, Gonc EN, Sen Y, Kandemir N. Inappropriate use of potent topical glucocorticoids in infants. J Pediatr Endocrinol Metab 2007;20:219-225. (Pubitemid 46865072)
188. Pinto HC, Baptista A, Camilo ME, de Costa EB, Valente A, de Moura MC. Tamoxifen-associated steatohepatitis - report of three cases. J Hepatol 1995;23:95-97.
189. Simon JB, Manley PN, Brien JF, Armstrong PW. Amiodarone hepatotoxicity simulating alcoholic liver disease. N Engl J Med 1984;311:167-172. (Pubitemid 14092908)
190. Maida I, Núñez M, Ríos MJ, Martín-Carbonero L, Sotgiu G, Toro C, et al. Severe liver disease associated with prolonged exposure to antiretroviral drugs. J Acquir Immune Defic Syndr 2006;42:177-182. (Pubitemid 43884712)
191. Pessayre D, Bichara M, Degott C, Potet F, Benhamou JP, Feldmann G. Perhexiline maleate-induced cirrhosis. Gastroenterology 1979;76:170-177. (Pubitemid 9129527)
192. Puli SR, Fraley MA, Puli V, Kuperman AB, Alpert MA. Hepatic cirrhosis caused by low-dose oral amiodarone therapy. Am J Med Sci 2005;330:257-261. (Pubitemid 41689456)
193. Yamamoto N, Oliveira MB, Campello Ade P, Lopes LC, Klüppel ML. Methotrexate: studies on the cellular metabolism. I. Effect on mitochondrial oxygen uptake and oxidative phosphorylation. Cell Biochem Funct 1988;6:61-66.
194. Hardwick JP, Osei-Hyiaman D, Wiland H, Abdelmegeed MA, Song BJ. PPAR/RXR regulation of fatty acid metabolism and fatty acid ω-hydroxylase (CYP4) isozymes: implications for prevention of lipotoxicity in fatty liver disease. PPAR Res 2009;2009:952734, doi:10.1155/2009/952734.
195. Leclercq IA, Farrel GC, Field J, Bell DR, Gonzalez FJ, Robertson GR. CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine nonalcoholic steatohepatitis. J Clin Invest 2000;105:1067-1075. (Pubitemid 30217691)
196. Berson A, De Beco V, Lettéron P, Robin MA, Moreau C, El Kahwaji J, et al. Steatohepatitis-inducing drugs cause mitochondrial dysfunction and lipid peroxidation in rat hepatocytes. Gastroenterology 1998;114:764-774. (Pubitemid 28160411)
197. Demori I, Voci A, Fugassa E, Burlando B. Combined effects of high-fat diet and ethanol induce oxidative stress in rat liver. Alcohol 2006;40:185-191. (Pubitemid 46528100)
198. Leonarduzzi G, Scavazza A, Biasi F, Chiarpotto E, Camandola S, Vogel S, et al. The lipid peroxidation end product 4-hydroxy-2,3-nonenal up-regulates transforming growth factor β1 expression in the macrophage lineage: a link between oxidative injury and fibrosclerosis. FASEB J 1997;11:851-857. (Pubitemid 27371894)
199. Mitchell C, Robin MA, Mayeuf A, Mahrouf-Yorgov M, Mansouri A, Hamard M, et al. Protection against hepatocyte mitochondrial dysfunction delays fibrosis progression in mice. Am J Pathol 2009;175:1929-1937.
200. Nieto N, Friedman SL, Cederbaum AI. Stimulation and proliferation of primary rat hepatic stellate cells by cytochrome P450 2E1-derived reactive oxygen species. Hepatology 2002;35:62-73. (Pubitemid 34032544)
201. Parola M, Pinzani M, Casini A, Albano E, Poli G, Gentilini A, et al. Stimulation of lipid peroxidation or 4-hydroxynonenal treatment increases procollagen alpha 1 (I) gene expression in human liver fat-storing cells. Biochem Biophys Res Commun 1993;194:1044-1050.
202. Chen J, Schenker S, Frosto TA, Henderson GI. Inhibition of cytochrome c oxidase activity by 4-hydroxynonenal (HNE). Role of HNE adduct formation with the enzyme subunits. Biochim Biophys Acta 1998;1380:336-344.
203. Comporti M. Three models of free radical-induced cell injury. Chem Biol Interact 1989;72:1-56. (Pubitemid 19284045)
204. Esterbauer H, Schaur RJ, Zollner H. Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radic Biol Med 1991;11:81-128. (Pubitemid 121003917)
205. Hruszkewycz AM. Evidence for mitochondrial DNA damage by lipid peroxidation. Biochem Biophys Res Commun 1988;153:191-197.
206. Sampey BP, Stewart BJ, Petersen DR. Ethanol-induced modulation of hepatocellular extracellular signal-regulated kinase-1/2 activity via 4-hydroxynonenal. J Biol Chem 2007;282:1925-1937. (Pubitemid 47076723)
207. Robin MA, Descatoire V, Pessayre D, Berson A. Steatohepatitis-inducing drugs trigger cytokeratin cross-links in hepatocytes. Possible contribution to Mallory-Denk body formation. Toxicol In Vitro 2008;22:1511-1519.
208. Black D, Lyman S, Qian T, Lemasters JJ, Rippe RA, Nitta T, et al. Transforming growth factor beta mediates hepatocyte apoptosis through Smad3 generation of reactive oxygen species. Biochimie 2007;89:1464-1473. (Pubitemid 350122858)
209. Bruno S, Maisonneuve P, Castellana P, Rotmensz N, Rossi S, Maggioni M, et al. Incidence and risk factors for non-alcoholic steatohepatitis: prospective study of 5408 women enrolled in Italian tamoxifen chemoprevention trial. BMJ 2005;330:932.
210. Fernandez FG, Ritter J, Goodwin JW, Linehan DC, Hawkins WG, Strasberg SM. Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases. J Am Coll Surg 2005;200:845-853. (Pubitemid 40744790)
211. Rosenberg P, Urwitz H, Johannesson A, Ros AM, Lindholm J, Kinnman N, et al. Psoriasis patients with diabetes type 2 are at high risk of developing liver fibrosis during methotrexate treatment. J Hepatol 2007;46:1111-1118. (Pubitemid 46669734)
212. Saphner T, Triest-Robertson S, Li H, Holzman P. The association of nonalcoholic steatohepatitis and tamoxifen in patients with breast cancer. Cancer 2009;115:3189-3195.
213. Gavrilova O, Haluzik M, Matsusue K, Cutson JJ, Johnson L, Dietz KR, et al. Liver peroxisome proliferator-activated receptor γ contributes to hepatic steatosis, triglyceride clearance, and regulation of body fat mass. J Biol Chem 2003;278:34268-34276. (Pubitemid 37553270)
214. Takamura T, Misu H, Matsuzawa-Nagata N, Sakurai M, Ota T, Shimizu A, et al. Obesity upregulates genes involved in oxidative phosphorylation in livers of diabetic patients. Obesity 2008;16:2601-2609.
215. Westerbacka J, Kolak M, Kiviluoto T, Arkkila P, Sirén J, Hamsten A, et al. Genes involved in fatty acid partitioning and binding, lipolysis, monocyte/macrophage recruitment, and inflammation are overexpressed in the human fatty liver of insulin-resistant subjects. Diabetes 2007;56:2759-2765. (Pubitemid 350044919)
216. Pessayre D, Fromenty B. NASH: a mitochondrial disease. J Hepatol 2005;42:928-940. (Pubitemid 40693212)
217. Moreira PI, Custodio J, Moreno A, Oliveira CR, Santos MS. Tamoxifen and estradiol interact with the flavin mononucleotide site of complex I leading to mitochondrial failure. J Biol Chem 2006;281:10143-10152. (Pubitemid 43864550)
218. Dai HF, Shen Z, Yu CH, Zhang XC, Li YM. Epidemiology of fatty liver in an islander population of China: a population-based case-control study. Hepatobiliary Pancreat Dis Int 2008;7:373-378.
219. Mallat A, Lotersztajn S. Cigarette smoke exposure: a novel cofactor of NAFLD progression? J Hepatol 2009;51:430-432.
220. Robin MA, Demeilliers C, Sutton A, Paradis V, Maisonneuve C, Dubois S, et al. Alcohol increases tumor necrosis factor alpha and decreases nuclear factor-κB to activate hepatic apoptosis in genetically obese mice. Hepatology 2005;42:1280-1290. (Pubitemid 43260030)
221. Anderson N, Borlak J. Drug-induced phospholipidosis. FEBS Lett 2006;580:5533-5540. (Pubitemid 44465910)
222. Kodavanti UP, Mehendale HM. Cationic amphiphilic drugs and phospholipid storage disorder. Pharmacol Rev 1990;42:327-354.
223. Guigui B, Perrot S, Berry JP, Fleury-Feith J, Martin N, Métreau JM, et al. Amiodarone-induced hepatic phospholipidosis: a morphological alteration independent of pseudoalcoholic liver disease. Hepatology 1988;8:1063-1068.
224. Ikeda K, Hirayama M, Hirota Y, Asa E, Seki J, Tanaka Y. Drug-induced phospholipidosis is caused by blockade of mannose 6-phosphate receptor-mediated targeting of lysosomal enzymes. Biochem Biophys Res Commun 2008;377:268-274.
225. Brennan AM, Lee JH, Tsiodras S, Chan JL, Doweiko J, Chimienti SN, et al. R-metHuLeptin improves highly active antiretroviral therapy-induced lipoatrophy and the metabolic syndrome, but not through altering circulating IGF and IGF-binding protein levels: observational and interventional studies in humans. Eur J Endocrinol 2009;160:173-176.
226. Mulligan K, Khatami H, Schwarz JM, Sakkas GK, DePaoli AM, Tai VW, et al. The effects of recombinant human leptin on visceral fat, dyslipidemia, and insulin resistance in patients with human immunodeficiency virus-associated lipoatrophy and hypoleptinemia. J Clin Endocrinol Metab 2009;94:1137-1144.
227. Igoudjil A, Abbey-Toby A, Begriche K, Grodet A, Chataigner K, Peytavin G, et al. High doses of stavudine induce fat wasting and mild liver damage without impairing mitochondrial respiration in mice. Antivir Ther 2007;12:389-400. (Pubitemid 46787984)
228. Ceddia RB, Koistinen HA, Zierath JR, Sweeney G. Analysis of paradoxical observations on the association between leptin and insulin resistance. FASEB J 2002;16:1163-1176. (Pubitemid 34815404)
229. Shimabukuro M, Koyama K, Chen G, Wang MY, Trieu F, Lee Y, et al. Direct antidiabetic effect of leptin through triglyceride depletion of tissues. Proc Natl Acad Sci USA 1997;94:4637-4641. (Pubitemid 27194295)
230. Christ-Crain M, Kola B, Lolli F, Fekete C, Seboek D, Wittmann G, et al. AMP-activated protein kinase mediates glucocorticoid-induced metabolic changes: a novel mechanism in Cushing's syndrome. FASEB J 2008;22:1672-1683. (Pubitemid 351811445)
231. Coll AP, Challis BG, Lopez M, Piper S, Yeo GS, O'Rahilly S. Prooiomelanocortin-deficient mice are hypersensitive to the adverse metabolic effects of glucocorticoids. Diabetes 2005;54:2269-2276. (Pubitemid 41134252)
232. Covar RA, Leung DY, McCormick D, Steelman J, Zeitler P, Spahn JD. Risk factors associated with glucocorticoid-induced adverse effects in children with severe asthma. J Allergy Clin Immunol 2000;106:651-659.
233. Shi JH, Du WH, Liu XY, Fan YP, Hu XL, Zhou HY, et al. Glucocorticoids decrease serum adiponectin level and WAT adiponectin mRNA expression in rats. Steroids 2010;75:853-858.
234. Dumortier J, Giostra E, Belbouab S, Morard I, Guillaud O, Spahr L, et al. Nonalcoholic fatty liver disease in liver transplant recipients: another story of "seed and soil". Am J Gastroenterol 2010;105:613-620.
235. Penfornis A, Kury-Paulin S. Immunosuppressive drug-induced diabetes. Diabetes Metab 2006;32:539-546. (Pubitemid 44836987)
236. Coccurello R, Caprioli A, Conti R, Ghirardi O, Borsini F, Carminati P, et al. Olanzapine (LY170053, 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[ 2,3-b][1,5] benzodiazepine), but not the novel atypical antipsychotic ST2472 (9-piperazin-1-ylpyrrolo[2, 1-b][1,3]benzothiazepine), chronic administration induces weight gain, hyperphagia, and metabolic dysregulation in mice. J Pharmacol Exp Ther 2008;326:905-911.
237. Reynolds GP, Kirk SL. Metabolic side effects of antipsychotic drug treatment - pharmacological mechanisms. Pharmacol Ther 2010;125:169-179.
238. Albaugh VL, Judson JG, She P, Lang CH, Maresca KP, Joyal JL, et al. Olanzapine promotes fat accumulation in male rats by decreasing physical activity, repartitioning energy and increasing adipose tissue lipogenesis while impairing lipolysis. Mol Psychiatry, in press. doi:10.1038/mp.2010.33.
239. Vestri HS, Maianu L, Moellering DR, Garvey WT. Atypical antipsychotic drugs directly impair insulin action in adipocytes: effects on glucose transport, lipogenesis, and antilipolysis. Neuropsychopharmacology 2007;32:765-772. (Pubitemid 46426168)
240. Yang LH, Chen TM, Yu ST, Chen YH. Olanzapine induces SREBP-1-related adipogenesis in 3T3-L1 cells. Pharmacol Res 2007;56:202-208.
241. Ferno J, Vik-Mo AO, Jassim G, Havik B, Berge K, Skrede S, et al. Acute clozapine exposure in vivo induces lipid accumulation and marked sequential changes in the expression of SREBP, PPAR, and LXR target genes in rat liver. Psychopharmacology 2009;203:73-84.
242. Holtmann M, Kopf D, Mayer M, Bechtinger E, Schmidt MH. Risperidone-associated steatohepatitis and excessive weight-gain. Pharmacopsychiatry 2003;36:206-207. (Pubitemid 37357369)
243. Kumra S, Herion D, Jacobsen LK, Briguglia C, Grothe D. Case study: risperidone-induced hepatotoxicity in pediatric patients. J Am Acad Child Adolesc Psychiatry 1997;36:701-705. (Pubitemid 27184079)
244. Shertzer HG, Kendig EL, Nasrallah HA, Johansson E, Genter MB. Protection from olanzapine-induced metabolic toxicity in mice by acetaminophen and tetrahydroindenoindole. Int J Obes 2010;34:970-979.
245. Lauressergues E, Staels B, Valeille K, Majd Z, Hum DW, Duriez P, et al. Antipsychotic drug action on SREBPs-related lipogenesis and cholesterogenesis in primary rat hepatocytes. Naunyn Schmiedebergs Arch Pharmacol 2010;381:427-439.
246. Raeder MB, Ferno J, Vik-Mo AO, Steen VM. SREBP activation by antipsychotic- and antidepressant-drugs in cultured human liver cells: relevance for metabolic side-effects? Mol Cell Biochem 2006;289:167-173.
247. Rauchenzauner M, Haberlandt E, Scholl-Bürgi S, Karall D, Schoenherr E, Tatarczyk T, et al. Effect of valproic acid treatment on body composition, leptin and the soluble leptin receptor in epileptic children. Epilepsy Res 2008;80:142-149.
248. Verrotti A, Manco R, Agostinelli S, Coppola G, Chiarelli F. The metabolic syndrome in overweight epileptic patients treated with valproic acid. Epilepsia 2010;51:268-273.
249. Lagace DC, McLeod RS, Nachtigal MW. Valproic acid inhibits leptin secretion and reduces leptin messenger ribonucleic acid levels in adipocytes. Endocrinology 2004;145:5493-5503. (Pubitemid 39564589)
250. Verrotti A, la Torre R, Trotta D, Mohn A, Chiarelli F. Valproate-induced insulin resistance and obesity in children. Horm Res 2009;71:125-131.
251. Luef GJ, Waldmann M, Sturm W, Naser A, Trinka E, Unterberger I, et al. Valproate therapy and nonalcoholic fatty liver disease. Ann Neurol 2004;55:729-732. (Pubitemid 38544334)
252. Luef G, Rauchenzauner M, Waldmann M, Sturm W, Sandhofer A, Seppi K, et al. Non-alcoholic fatty liver disease (NAFLD), insulin resistance and lipid profile in antiepileptic drug treatment. Epilepsy Res 2009;86:42-47.
253. Sato K, Ueda Y, Ueno K, Okamoto K, Iizuka H, Katsuda S. Hepatocellular carcinoma and nonalcoholic steatohepatitis developing during long-term administration of valproic acid. Virchows Arch 2005;447:996-999. (Pubitemid 41719556)
254. Verrotti A, Di Marco G, la Torre R, Pelliccia P, Chiarelli F. Nonalcoholic fatty liver disease during valproate therapy. Eur J Pediatr 2009;168:1391-1394.
255. Shen Z, Liang X, Rogers CQ, Rideout D, You M. Involvement of adiponectin-SIRT1-AMPK signaling in the protective action of rosiglitazone against alcoholic fatty liver in mice. Am J Physiol Gastrointest Liver Physiol 2010;298:G364-G374.
256. Cahill A, Cunningham CC, Adachi M, Ishii H, Bailey SM, Fromenty B, et al. Effects of alcohol and oxidative stress on liver pathology: the role of the mitochondrion. Alcohol Clin Exp Res 2002;26:907-915. (Pubitemid 34666152)
257. Dunn W, Xu R, Schwimmer JB. Modest wine drinking and decreased prevalence of suspected nonalcoholic fatty liver disease. Hepatology 2008;47:1947-1954. (Pubitemid 351945562)
258. Fromenty B, Vadrot N, Massart J, Turlin B, Barri-Ova N, Lettéron P, et al. Chronic ethanol consumption lessens the gain of body weight, liver triglycerides, and diabetes in obese ob/ob mice. J Pharmacol Exp Ther 2009;331:23-34.
259. Howard AA, Arnsten JH, Gourevitch MN. Effect of alcohol consumption on diabetes mellitus: a systematic review. Ann Intern Med 2004;140:211-219.
260. Lewis JH, Zimmerman HJ, Garrett CT, Rosenberg E. Valproate-induced hepatic steatogenesis in rats. Hepatology 1982;2:870-873. (Pubitemid 13204383)
261. Schultz JC, Adamson JS, Workman WW, Norman TD. Fatal liver disease after intravenous administration of tetracycline in high dosage. N Engl J Med 1963;269:999-1004.
262. Willmore LJ, Wilder BJ, Bruni J, Villarreal HJ. Effect of valproic acid on hepatic function. Neurology 1978;28:961-964. (Pubitemid 8389835)
263. Brien JF, Jimmo S, Brennan FJ, Ford SE, Armstrong PW. Distribution of amiodarone and its metabolite, desethylamiodarone, in human tissues. Can J Physiol Pharmacol 1987;65:360-364. (Pubitemid 17068310)
264. Nattel S, Talajic M. Recent advances in understanding the pharmacology of amiodarone. Drugs 1988;36:121-131.
265. Gilinsky NH, Briscoe GW, Kuo CS. Fatal amiodarone hepatoxicity. Am J Gastroenterol 1988;83:161-163. (Pubitemid 18063507)
266. Boubaker K, Flepp M, Sudre P, Furrer H, Haensel A, Hirschel B, et al. Hyperlactatemia and antiretroviral therapy: the Swiss HIV Cohort Study. Clin Infect Dis 2001;33:1931-1937. (Pubitemid 33105136)
267. Kovari H, Ledergerber B, Battegay M, Rauch A, Hirschel B, Foguena AK, et al. Incidence and risk factors for chronic elevation of alanine aminotransferase levels in HIV-infected persons without hepatitis B or C virus co-infection. Clin Infect Dis 2010;50:502-511.
268. Morgan MY, Reshef R, Shah RR, Oates NS, Smith RL, Sherlock S. Impaired oxidation of debrisoquine in patients with perhexiline liver injury. Gut 1984;25:1057-1064. (Pubitemid 14002119)
269. Ohnishi T, Ogawa Y, Saibara T, Nishioka A, Kariya S, Fukumoto M, et al. CYP17 polymorphism as a risk factor of tamoxifen-induced hepatic steatosis in breast cancer patients. Oncol Rep 2005;13:485-489.
270. Watanabe I, Tomita A, Shimizu M, Sugawara M, Yasumo H, Koishi R, et al. A study to survey susceptible genetic factors responsible for troglitazone-associated hepatotoxicity in Japanese patients with type 2 diabetes mellitus. Clin Pharmacol Ther 2003;73:435-455. (Pubitemid 36549828)
271. Lucena MI, Andrade RJ, Martínez C, Ulzurrun E, García-Martín E, Borraz Y, et al. Glutathione S-transferase M1 and T1 null genotypes increase susceptibility to idiosyncratic drug-induced liver injury. Hepatology 2008;48:588-596.
272. Ho PC, Abbott FS, Zanger UM, Chang TK. Influence of CYP2C9 genotypes on the formation of a hepatotoxic metabolite of valproic acid in human liver microsomes. Pharmacogenomics J 2003;3:335-342. (Pubitemid 38072171)
273. Finsterer J, Segall L. Drugs interfering with mitochondrial disorders. Drug Chem Toxicol 2010;33:138-151.
274. Njolstad PR, Skjeldal OH, Agsteribbe E, Huckriede A, Wannag E, Sovik O, et al. Medium-chain acyl-CoA dehydrogenase deficiency and fatal valproate toxicity. Pediatr Neurol 1997;16:160-162. (Pubitemid 27137456)
275. Krähenbühl S, Brandner S, Kleinle S, Liechti S, Straumann D. Mitochondrial diseases represent a risk factor for valproate-induced fulminant liver failure. Liver 2000;20:346-348. (Pubitemid 30488006)
276. McFarland R, Hudson G, Taylor RW, Green SH, Hodges S, McKiernan PJ, et al. Reversible valproate hepatotoxicity due to mutations in mitochondrial DNA polymerase c (POLG1). Arch Dis Child 2009;93:151-153.
277. Stewart JD, Horvath R, Baruffini E, Ferrero I, Bulst S, Watkins PB, et al. Polymerase c gene POLG determines the risk of sodium valproate-induced liver toxicity. Hepatology 2010;52:1791-1796.
278. Bailey CM, Kasiviswanathan R, Copeland WC, Anderson KS. R964C mutation of DNA polymerase c imparts increased stavudine toxicity by decreasing nucleoside analog discrimination and impairing polymerase activity. Antimicrob Agents Chemother 2009;53:2610-2612.
279. Yamanaka H, Gatanaga H, Kosalaraksa P, Matsuoka-Aizawa S, Takahashi T, Kimura S, et al. Novel mutation of human DNA polymerase gamma associated with mitochondrial toxicity induced by anti-HIV treatment. J Infect Dis 2007;195:1419-1425. (Pubitemid 46717459)
280. +/- mouse: modeling the mitochondrial role in drug toxicity. Drug Discov Today 2008;13:982-988.
281. Degoul F, Sutton A, Mansouri A, Cepanec C, Degott C, Fromenty B, et al. Homozygosity for alanine in the mitochondrial targeting sequence of superoxide dismutase and risk for severe alcoholic liver disease. Gastroenterology 2001;120:1468-1474. (Pubitemid 32322321)
282. Huang YS, Su WJ, Huang YH, Chen CY, Chang FY, Lin HC, et al. Genetic polymorphisms of manganese superoxide dismutase, NAD(P)H:quinone oxidoreductase, glutathione S-transferase M1 and T1, and the susceptibility to drug-induced liver injury. J Hepatol 2007;47:128-134.
283. Sutton A, Khoury H, Prip-Buus C, Cepanec C, Pessayre D, Degoul F. The Ala16Val genetic dimorphism modulates the import of human manganese superoxide dismutase into rat liver mitochondria. Pharmacogenetics 2003;13:145-157. (Pubitemid 36324244)
284. de Leon J, Correa JC, Ruano G, Windemuth A, Arranz MJ, Diaz FJ. Exploring genetic variations that may be associated with the direct effects of some antipsychotics on lipid levels. Schizophr Res 2008;98:40-46. (Pubitemid 350235904)
285. Klein KM, Hamer HM, Reis J, Schmidtke J, Oertel WH, Theisen FM, et al. Weight change in monozygotic twins treated with valproate. Obes Res 2005;13:1330-1334.
286. Templeman LA, Reynolds GP, Arranz B, San L. Polymorphisms of the 5-HT2C receptor and leptin genes are associated with antipsychotic drug-induced weight gain in Caucasian subjects with a first-episode psychosis. Pharmacogenet Genomics 2005;15:195-200. (Pubitemid 40569890)
287. Eghtesadi-Araghi P, Sohrabpour A, Vahedi H, Saberi-Firoozi M. Halothane hepatitis in Iran: a review of 59 cases. World J Gastroenterol 2008;14:5322-5326.
288. Moult PJ, Sherlock S. Halothane-related hepatitis. A clinical study of twenty-six cases. Q J Med 1975;44:99-114.
289. Walton B, Simpson BR, Strunin L, Doniach D, Perrin J, Appleyard AJ. Unexplained hepatitis following halothane. Br Med J 1976;1:1171-1176.
290. Nguyen GC, Sam J, Thuluvath PJ. Hepatitis C is a predictor of acute liver injury among hospitalisations for acetaminophen overdose in the United States: a nationwide analysis. Hepatology 2008;48:1336-1341.
291. Forget P, Wittebole X, Laterre PF. Therapeutic dose of acetaminophen may induce fulminant hepatitis in the presence of risk factors: a report of two cases. Br J Anaesth 2009;103:899-900.
292. Tarantino G, Conca P, Basile V, Gentile A, Capone D, Polichetti G, et al. A prospective study of acute drug-induced liver injury in patients suffering from non-alcoholic fatty liver disease. Hepatol Res 2007;37:410-415. (Pubitemid 46915785)
293. El-Serag HB, Everhart JE. Diabetes increases the risk of acute hepatic failure. Gastroenterology 2002;122:1822-1828. (Pubitemid 34651427)
294. Kent PD, Luthra HS, Michet C. Risk factors for methotrexate-induced abnormal laboratory monitoring results in patients with rheumatoid arthritis. J Rheumatol 2004;31:1727-1731. (Pubitemid 39202512)
295. Langman G, Hall PM, Todd G. Role of non-alcoholic steatohepatitis in methotrexate-induced liver injury. J Gastroenterol Hepatol 2001;16:1395-1401. (Pubitemid 34107409)
296. Mattar W, Juliar B, Gradus-Pizlo I, Kwo PY. Amiodarone hepatotoxicity in the context of the metabolic syndrome and right-sided heart failure. J Gastrointestin Liver Dis 2009;18:419-423.
297. Ito M, Suzuki J, Sasaki M, Watanabe K, Tsujioka S, Takahashi Y, et al. Development of nonalcoholic steatohepatitis model through combination of high-fat diet and tetracycline with morbid obesity in mice. Hepatol Res 2006;34:92-98. (Pubitemid 43137557)
298. Sugatani J, Wada T, Osabe M, Yamakawa K, Yoshinari K, Miwa M. Dietary inulin alleviates hepatic steatosis and xenobiotics-induced liver injury in rats fed a high-fat and high-sucrose diet: association with the suppression of hepatic cytochrome P450 and hepatocyte nuclear factor 4α expression. Drug Metab Dispos 2006;34:1677-1687. (Pubitemid 44427470)
299. Hanagama M, Inoue H, Kamiya M, Shinone K, Nata M. Gene expression on liver toxicity induced by administration of haloperidol in rats with severe fatty liver. Leg Med 2008;10:177-184.
300. Carmiel-Haggai M, Cederbaum AI, Nieto N. Binge ethanol exposure increases liver injury in obese rats. Gastroenterology 2003;125:1818-1833. (Pubitemid 37500446)
301. Malaguarnera L, Madeddu R, Palio E, Arena N, Malaguarnera M. Heme oxygenase-1 levels and oxidative stress-related parameters in non-alcoholic fatty liver disease patients. J Hepatol 2005;42:585-591. (Pubitemid 40342940)
302. Younossi ZM, Baranova A, Ziegler K, Del Giacco L, Schlauch K, Born TL, et al. A genomic and proteomic study of the spectrum of nonalcoholic fatty liver disease. Hepatology 2005;42:665-674. (Pubitemid 41233660)
303. James LP, Mayeux PR, Hinson JA. Acetaminophen-induced hepatotoxicity. Drug Metab Dispos 2003;31:1499-1506. (Pubitemid 37466918)
304. Koop DR. Oxidative and reductive metabolism by cytochrome P450 2E1. FASEB J 1992;6:724-730.
305. Lee SS, Buters JT, Pineau T, Fernandez-Salguero P, Gonzalez FJ. Role of CYP2E1 in the hepatotoxicity of acetaminophen. J Biol Chem 1996;271:12063-12067. (Pubitemid 26157285)
306. Spracklin DK, Hankins DC, Fisher JM, Thummel KE, Kharasch ED. Cytochrome P450 2E1 is the principal catalyst of human oxidative halothane metabolism in vitro. J Pharmacol Exp Ther 1997;281:400-411.
307. Chalasani N, Gorski JC, Asghar MS, Asghar A, Foresman B, Hall SD, et al. Hepatic cytochrome P450 2E1 activity in nondiabetic patients with nonalcoholic steatohepatitis. Hepatology 2003;37:544-550. (Pubitemid 36258775)
308. Emery MG, Fisher JM, Chien JY, Kharasch ED, Dellinger EP, Kowdley KV, et al. CYP2E1 activity before and after weight loss in morbidly obese subjects with nonalcoholic fatty liver disease. Hepatology 2003;38:428-435. (Pubitemid 36919864)
309. Videla LA, Rodrigo R, Orellana M, Fernandez V, Tapia G, Quinones L, et al. Oxidative stress-related parameters in the liver of non-alcoholic fatty liver disease patients. Clin Sci 2004;106:261-268. (Pubitemid 38365832)
310. Weltman MD, Farrell GC, Hall P, Ingelman-Sundberg M, Liddle C. Hepatic cytochrome P450 2E1 is increased in patients with nonalcoholic steatohepatitis. Hepatology 1998;27:128-133. (Pubitemid 28041545)
311. Bentley JB, Vaughan RW, Gandolfi AJ, Cork RC. Halothane biotransformation in obese and nonobese patients. Anesthesiology 1982;57:94-97. (Pubitemid 12041004)
312. Abernethy DR, Divoll M, Greenblatt DJ, Ameer B. Obesity, sex, and acetaminophen disposition. Clin Pharmacol Ther 1982;31:783-790. (Pubitemid 13096695)
313. Abernethy DR, Greenblatt DJ, Divoll M, Shader RI. Enhanced glucuronide conjugation of drugs in obesity: studies of lorazepam, oxazepam, and acetaminophen. J Lab Clin Med 1983;101:873-880. (Pubitemid 13100682)
314. Lee WH, Kramer WG, Granville GE. The effect of obesity on acetaminophen pharmacokinetics in man. J Clin Pharmacol 1981;21:284-287. (Pubitemid 11013036)
315. Corcoran GB, Wong BK. Obesity as a risk factor in drug-induced organ injury: increased liver and kidney damage by acetaminophen in the obese overfed rat. J Pharmacol Exp Ther 1987;241:921-927.
316. Kon K, Ikejima K, Okumura K, Arai K, Aoyama T, Watanabe S. Diabetic KK-Ay mice are highly susceptible to oxidative hepatocellular damage induced by acetaminophen. Am J Physiol Gastrointest Liver Physiol 2010;299:G329-G337.
317. Blouin RA, Dickson P, McNamara PJ, Cibull M, McClain C. Phenobarbital induction and acetaminophen hepatotoxicity: resistance in the obese Zucker rodent. J Pharmacol Exp Ther 1987;243:565-570. (Pubitemid 18011540)
318. Ito Y, Abril ER, Bethea NW, McCuskey MK, McCuskey RS. Dietary steatotic liver attenuates acetaminophen hepatotoxicity in mice. Microcirculation 2006;13:19-27. (Pubitemid 43050887)
319. Enriquez A, Leclercq I, Farrell GC, Robertson G. Altered expression of hepatic CYP2E1 and CYP4A in obese, diabetic ob/ob mice, and fa/fa Zucker rats. Biochem Biophys Res Commun 1999;255:300-306. (Pubitemid 29292254)
320. Leclercq IA, Field J, Enriquez A, Farrell GC, Robertson GR. Constitutive and inducible expression of hepatic CYP2E1 in leptin-deficient ob/ob mice. Biochem Biophys Res Commun 2000;268:337-344. (Pubitemid 30119623)
321. Robin MA, Sauvage I, Grandperret T, Descatoire V, Pessayre D, Fromenty B. Ethanol increases mitochondrial cytochrome P450 2E1 in mouse liver and rat hepatocytes. FEBS Lett 2005;579:6895-6902. (Pubitemid 41773706)
322. Zaluzny L, Farrell GC, Murray M. Effect of genetic obesity and experimental diabetes on hepatic microsomal mixed function oxidase activities. J Gastroenterol Hepatol 1990;5:256-263. (Pubitemid 20375186)
323. Labarga P, Soriano V, Vispo ME, Pinilla J, Martin-Carbonero L, Castellares C, et al. Hepatotoxicity of antiretroviral drugs is reduced after successful treatment of chronic hepatitis C in HIV-infected patients. J Infect Dis 2007;196:670-676. (Pubitemid 47293847)
324. Nunez M, Lana R, Mendoza JL, Martín-Carbonero L, Soriano V. Risk factors for severe hepatic injury after introduction of highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2001;27:426-431. (Pubitemid 32801070)
325. Banasch M, Emminghaus R, Ellrichmann M, Schmidt WE, Goetze O. Longitudinal effects of hepatitis C virus treatment on hepatic mitochondrial dysfunction assessed by C-methionine breath test. Aliment Pharmacol Ther 2008;28:443-449. (Pubitemid 352033277)
326. Diamond DL, Jacobs JM, Paeper B, Proll SC, Gritsenko MA, et al. Proteomic profiling of human liver biopsies: hepatitis C virus-induced fibrosis and mitochondrial dysfunction. Hepatology 2007;46:649-657. (Pubitemid 47436109)
327. You M, Crabb DW. Molecular mechanisms of alcoholic fatty liver: role of sterol regulatory element-binding proteins. Alcohol 2004;34:39-43.
328. Halfon P, Pénaranda G, Carrat F, Bedossa P, Bourlière M, Ouzan D, et al. Influence of insulin resistance on hepatic fibrosis and steatosis in hepatitis C virus (HCV) mono-infected compared with HIV-HCV co-infected patients. Aliment Pharmacol Ther 2009;30:61-70.
329. Mirandola S, Realdon S, Iqbal J, Gerotto M, Dal Pero F, Bortoletto G, et al. Liver microsomal triglyceride transfer protein is involved in hepatitis C liver steatosis. Gastroenterology 2006;130:1661-1669. (Pubitemid 43668848)
330. Rumack BH. Acetaminophen misconceptions. Hepatology 2004;40:10-15. (Pubitemid 38868916)
331. West SG. Methotrexate hepatotoxicity. Rheum Dis Clin North Am 1997;23:883-915. (Pubitemid 27490247)
332. David-Josephy P. The molecular toxicology of acetaminophen. Drug Metab Rev 2005;37:581-594.
333. Gonzalez FJ. Role of cytochromes P450 in chemical toxicity and oxidative stress: studies with CYP2E1. Mutat Res 2005;569:101-110. (Pubitemid 39643260)
334. Tanaka E, Yamazaki K, Misawa S. Update: the clinical importance of acetaminophen hepatotoxicity in non-alcoholic and alcoholic subjects. J Clin Pharm Ther 2000;25:325-332. (Pubitemid 32002876)
335. Nadanaciva S, Bernal A, Aggeler R, Capaldi R, Will Y. Target identification of drug induced mitochondrial toxicity using immunocapture based OXPHOS activity assays. Toxicol In Vitro 2007;21:902-911. (Pubitemid 46603229)
336. Dykens JA, Marroquin LD, Will Y. Strategies to reduce late-stage drug attrition due to mitochondrial toxicity. Expert Rev Mol Diagn 2007;7:161-175. (Pubitemid 46513443)
337. Fromenty B, Berson A, Pessayre D. Microvesicular steatosis and steatohepatitis: role of mitochondrial dysfunction and lipid peroxidation. J Hepatol 1997;26:13-22. (Pubitemid 127777233)
338. Hoogerwerf WA. Role of biological rhythms in gastrointestinal health and disease. Rev Endocr Metab Disord 2009;10:293-300.
339. Scheving LA. Biological clocks and the digestive system. Gastroenterology 2000;119:536-549. (Pubitemid 30622004)
340. Chen P, Li C, Pang W, Zhao Y, Dong W, Wang S, et al. The protective role of Per2 against carbon tetrachloride-induced hepatotoxicity. Am J Pathol 2009;174:63-70.
341. Kakan X, Chen P, Zhang J. Clock gene mPer2 functions in diurnal variation of acetaminophen induced hepatotoxicity in mice. Exp Toxicol Pathol, in press. doi:10.1016/j.etp.2010.04.011.
342. Le Martelot G, Claudel T, Gatfield D, Schaad O, Kornmann B, Sasso GL, et al. PLoS Biol 2009;7:e1000181.
343. Sutton GM, Begriche K, Kumar KG, Gimble JM, Perez-Tilve D, Nogueiras R, et al. Central nervous system melanocortin-3 receptors are required for synchronizing metabolism during entrainment to restricted feeding during the light cycle. FASEB J 2010;24:862-872.
344. Almon RR, Yang E, Lai W, Androulakis IP, DuBois DC, Jusko WJ. Circadian variations in rat liver gene expression: relationships to drug actions. J Pharmacol Exp Ther 2008;326:700-716.
345. Iurisci I, Filipski E, Sallam H, Harper F, Guettier C, Maire I, et al. Liver circadian clock, a pharmacologic target of cyclin-dependent kinase inhibitor seliciclib. Chronobiol Int 2009;26:1169-1188.
346. Kaplowitz N. Idiosyncratic drug hepatotoxicity. Nat Rev Drug Discov 2005;4:489-499. (Pubitemid 40861991)
347. Senior JR. What is idiosyncratic hepatotoxicity? What is it not? Hepatology 2008;47:1813-1815.
348. Dixit R, Boelsterli UA. Healthy animals and animal models of human disease(s) in safety assessment of human pharmaceuticals, including therapeutic antibodies. Drug Discov Today 2007;12:336-342. (Pubitemid 46476874)
349. Uetrecht J. Idiosyncratic drug reactions: past, present, and future. Chem Res Toxicol 2008;21:84-92. (Pubitemid 351219710)
350. Verma S, Kaplowitz N. Diagnosis, management and prevention of druginduced liver injury. Gut 2009;58:1555-1564.